RGT Wealth Advisors’s AbbVie ABBV Stock Holding History

RGT Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$289K	Buy	2,150 +15	+0.7%	+$2.15K	0.05%	60
2022 Q2	$327K	Sell	2,135 -126	-6%	-$19.3K	0.05%	65
2022 Q1	$367K	Buy	2,261 +126	+6%	+$18.3K	0.06%	63
2021 Q4	$289K	Hold	2,135	–	–	0.04%	74
2021 Q3	$230K	Sell	2,135 -909	-30%	-$104K	0.05%	45
2021 Q2	$343K	Sell	3,044 -103	-3%	-$11.6K	0.06%	34
2021 Q1	$341K	Sell	3,147 -918	-23%	-$98.2K	0.07%	33
2020 Q4	$436K	Buy	+4,065	New	+$391K	0.09%	36
2020 Q3	–	Sell	-2,358	Closed	-$232K	–	41
2020 Q2	$232K	Buy	+2,358	New	+$208K	0.07%	33
2016 Q4	–	Sell	-3,794	Closed	-$239K	–	123
2016 Q3	$239K	Buy	+3,794	New	+$246K	0.15%	90

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RGT Wealth Advisors's ABBV Position: Q3 2022 in Review

RGT Wealth Advisors increased its AbbVie (ABBV) stake by 0.7% in Q3 2022, buying an estimated $2.15K and bringing the position to 2,150 shares worth $289K. The position accounts for 0.05% of the portfolio, ranked #60.

RGT Wealth Advisors first reported a position in ABBV in Q3 2016 and has held it in 10 quarters since. The position peaked at $436K in Q4 2020. 2,969 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

RGT Wealth Advisors held 2,150 shares of AbbVie worth $289K as of Q3 2022.
RGT Wealth Advisors bought 15 AbbVie shares in Q3 2022, an estimated $2.15K.
AbbVie made up 0.05% of RGT Wealth Advisors's portfolio in Q3 2022, its #60 holding.
RGT Wealth Advisors first reported a position in AbbVie in Q3 2016 and has held it in 10 quarters since.
RGT Wealth Advisors's AbbVie position peaked at $436K in Q4 2020.
2,969 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on RGT Wealth Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.